Surface Plasmon Resonance (SPR) for Viral Antigen-Antibody Kinetics

Overview and Principles of Surface Plasmon Resonance (SPR) for Viral Antigen-Antibody Kinetics

Surface plasmon resonance (SPR) represents a transformative optical biosensing modality that has become an indispensable tool in the characterization of viral antigen-antibody interactions, particularly within the context of veterinary virology and translational vaccine development. At its core, SPR exploits the phenomenon of evanescent wave generation at the interface between a thin noble metal film-typically gold or silver-and a dielectric medium, most commonly a buffer solution or biological fluid. When plane-polarized light strikes this interface at a precise angle, the energy is transferred to electrons in the metal film, generating surface plasmons and causing a sharp reduction in reflected light intensity-the resonance angle or wavelength. This resonance condition is exquisitely sensitive to changes in refractive index within approximately 300 nm of the sensor surface, enabling the real-time, label-free monitoring of molecular interactions as they occur [5, 7, 10, 16]. The Kretschmann configuration, wherein the metal film is deposited directly onto a glass prism, remains the most widely employed geometry for commercial SPR instruments, including the Biacore series (Cytiva) and the MI-S200D (Inter-Bio), both of which have been rigorously compared and found to produce comparable kinetic data for antibody-antigen interactions [5].

The fundamental principle governing SPR-based kinetic analysis is the precise measurement of refractive index changes as a function of time. As an analyte-such as a viral antigen or antibody-binds to an immobilized ligand on the sensor chip surface, the local refractive index increases proportionally to the mass of bound material, generating a response unit (RU) signal that is directly proportional to the surface concentration of the bound molecule [1, 4, 7]. This signal is recorded continuously during both the association phase, where the analyte is injected over the ligand surface, and the dissociation phase, where buffer flow removes unbound analyte, allowing the construction of a sensogram or binding curve. From these real-time curves, the fundamental kinetic parameters-the association rate constant (kₐ), the dissociation rate constant (k_d), and the equilibrium dissociation constant (K_D = k_d/kₐ)-are extracted through nonlinear regression fitting to appropriate binding models, most commonly the simple 1:1 Langmuir interaction model [5, 16, 18]. The power of SPR lies in its ability to resolve the individual rate constants that comprise overall affinity; a low K_D may result from a rapid association (high kₐ), a slow dissociation (low k_d), or a combination of both, each of which carries distinct biological implications for antiviral immunity [1-3, 6, 11].

A critical consideration in the application of SPR to viral antigen-antibody kinetics is the physical form of the viral antigen itself. Unlike purified recombinant proteins or peptides, intact viral particles present a complex, multivalent surface that can dramatically influence binding kinetics through avidity effects. When whole virions are used as the analyte, or when viral antigens are immobilized at high density, bivalent or multivalent binding of antibodies can occur, leading to an apparent increase in overall affinity that reflects cooperative binding rather than intrinsic monovalent interaction [4, 18]. This phenomenon has been elegantly demonstrated in studies of Avian Influenza Virus, where SPR analysis of polyclonal sera from heterologous prime-boost vaccination revealed that dissociation rates (a surrogate for antibody affinity) were significantly improved by adjuvant-containing vaccine regimens, with strong inverse correlations between off-rates and virus neutralization titers [2, 3]. Similarly, work with inactivated poliovirus vaccine strains has shown that the high-affinity interaction of inactivated virions with oriented antibodies reflects the preservation of native D-antigen conformation, with K_D values as low as 1.04 × 10⁻¹¹ M observed for type 2 Sabin strain [1].

The operational principles of SPR also require careful consideration of mass transport limitations, which can confound kinetic measurements when the rate of analyte diffusion to the sensor surface is slower than the intrinsic binding rate. Under such conditions, the observed association rate becomes limited by mass transport rather than by the true kₐ, leading to artificially rapid binding curves and inaccurate parameter estimation [16, 20]. This is particularly relevant for large viral antigens such as the hemagglutinin (HA) trimer of Avian Influenza Virus or the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which have molecular weights exceeding 100 kDa and thus diffuse more slowly than small peptide fragments [8, 12, 13, 19]. Mitigation strategies include reducing the ligand immobilization density to minimize the local depletion of analyte, increasing the flow rate to enhance mass transport, and employing single-cycle kinetics (SCK) protocols that inject increasing concentrations of analyte without regeneration between injections [16, 20]. Instruments such as the Biacore T100 and the ProteOn XPR36 offer sophisticated fluidics that can be optimized to minimize mass transport artifacts, while the Octet system, based on bio-layer interferometry (BLI), provides an alternative high-throughput format where the sensor tips are immersed in analyte solutions, eliminating continuous flow and its associated mass transport complications [16, 20].

Another foundational principle is the management of non-specific binding (NSB), which poses a persistent challenge when analyzing complex biological matrices such as serum, plasma, or tissue homogenates. The high protein content and ionic diversity of these samples can generate refractive index changes unrelated to specific antigen-antibody interactions, corrupting the kinetic signal [9, 15, 19]. Advances in surface chemistry, including the use of polyethylene glycol (PEG)-based self-assembled monolayers, carboxymethylated dextran matrices, and peptide-based antifouling layers such as 3-MPA-LHDLHD-OH, have substantially reduced NSB [9, 19]. Moreover, sophisticated referencing strategies-employing a parallel flow cell with an immobilized non-cognate target or a blank surface-enable the subtraction of NSB contributions, allowing accurate determination of active antibody concentrations and affinities even in the nanomolar range [9]. This is critical for serological applications where the goal is to measure the kinetics of polyclonal antibodies against viral antigens directly from patient or animal sera, as demonstrated in studies of anti-HLA antibodies and anti-SARS-CoV-2 antibody responses [9, 19].

The interpretation of SPR data for viral antigen-antibody kinetics also demands an understanding of the structural heterogeneity inherent in viral targets. Viral surface proteins are frequently glycosylated, and the presence of N-linked and O-linked glycans can influence binding kinetics by shielding epitopes, altering protein conformation, or directly participating in the interaction. For example, studies on a human IgG4 monoclonal antibody demonstrated that complete deglycosylation with PNGase F did not significantly alter the equilibrium binding constant (K_D = 1.81 × 10⁻⁹ M for native versus 1.96 × 10⁻⁹ M for deglycosylated), indicating that Fc glycans do not contribute to antigen binding in that particular system [14]. However, for many viral antigens, particularly those of enveloped viruses, glycosylation patterns can vary between strains and production systems, leading to differential kinetic profiles that must be accounted for when comparing recombinant versus native antigens [17]. This has profound implications for the development of diagnostic assays and vaccines against viruses such as African Swine Fever Virus, Porcine Reproductive and Respiratory Syndrome Virus, and Infectious Bursal Disease Virus, where glycosylation heterogeneity may affect antibody recognition and neutralization [3, 17].

In summary, the principles of SPR for viral antigen-antibody kinetics are rooted in the precise, real-time measurement of refractive index changes at a metal-dielectric interface, yielding kinetic rate constants that define the strength, speed, and stability of the interaction. Mastery of these principles-including the physical optics of plasmon resonance, the management of mass transport and non-specific binding, the appropriate choice of binding models (1:1 Langmuir, bivalent analyte, or heterogeneous ligand), and the biological context of antigen structure and glycosylation-is essential for generating reliable, reproducible, and biologically meaningful data that can inform vaccine design, therapeutic antibody development, and serological diagnostics [1-6, 8-21].

Experimental Design and Protocol for SPR-Based Kinetic Analysis of Viral Antigen-Antibody Interactions

The rigorous design of surface plasmon resonance (SPR) experiments for characterizing viral antigen-antibody interactions is a multifaceted endeavor that demands meticulous attention to every phase of the analytical workflow. As a veterinary clinical pathologist, I approach this not merely as a biophysical measurement but as a diagnostic and investigative tool with profound implications for vaccine development, therapeutic antibody selection, and serological surveillance. The protocols described herein are synthesized from decades of methodological refinement and are tailored specifically for the unique challenges posed by viral targets-their structural complexity, potential for conformational lability, and the often polyclonal nature of the host immune response.

Foundational Principles and Experimental Aims

The core objective of any SPR-based kinetic analysis is the determination of the association rate constant (ka), dissociation rate constant (kd), and the equilibrium dissociation constant (KD = kd/ka) that define the interaction between a viral antigen and its cognate antibody. However, the experimental design must be guided by the specific biological question. For instance, characterizing the affinity of a monoclonal antibody (mAb) for a recombinant viral surface protein, such as the hemagglutinin (HA) of Avian Influenza Virus, demands a different approach than profiling the polyclonal serum response from a vaccinated animal against a complex viral particle like Infectious Salmon Anemia Virus. The former typically employs a direct binding format with the antigen immobilized, while the latter may require an indirect capture method to orient antibodies uniformly and avoid denaturation of the viral epitope [1, 3].

A critical preliminary decision is the choice of immobilization strategy. For viral antigens, particularly those that are labile or conformation-dependent, the method of attachment to the sensor chip surface can profoundly influence the measured kinetics. The work by Gnedenko et al. [1] on inactivated poliovirus vaccine strains elegantly demonstrates this principle. By immobilizing oriented antibodies via their Fc fragments to protein A, they preserved the native structure of the D-antigen on the viral particle, achieving high-affinity interactions with KD values in the low picomolar range (1.04 × 10⁻¹¹ M for type 2 Sabin strain). This approach is superior to random amine coupling, which can sterically hinder the antigen-binding sites or induce conformational changes in the viral capsid. For enveloped viruses like Porcine Reproductive and Respiratory Syndrome Virus or Equine Influenza A Virus, direct immobilization of the whole virion is often avoided due to the risk of disrupting the lipid envelope and exposing non-native epitopes. Instead, recombinant forms of the major glycoproteins (e.g., GP5 or HA) are preferred as the immobilized ligand [2, 3].

Sensor Chip Surface Chemistry and Ligand Immobilization Protocols

The selection of the sensor chip and the surface chemistry is the first tangible step in protocol development. Standard CM5 (carboxymethylated dextran) chips are the workhorse for most applications, providing a hydrophilic, three-dimensional matrix that enhances ligand capacity and reduces non-specific binding (NSB). However, for viral antigens that are particularly sticky or for work with complex matrices like serum, alternative surfaces may be necessary. The use of a low-density, short-chain carboxymethylated surface (e.g., CM3 or CM4 chips) can minimize mass transport limitations and rebinding effects, which are notorious for skewing kinetic parameters, especially for high-affinity interactions [16, 20]. For example, in the characterization of anti-HLA antibodies from transplant patients, Visentin et al. [9] demonstrated that even with extensive serum pre-treatment, NSB remained a significant obstacle. They developed a method using a non-cognate target captured on a separate flow cell to mathematically subtract the NSB contribution, a technique directly applicable to viral serology where sera from infected animals often contain cross-reactive antibodies.

The immobilization protocol itself must be optimized for each viral antigen. The standard amine coupling method, which targets primary amines on lysine residues, is straightforward but can be detrimental if the antigen's functional epitopes are lysine-rich. For the spike S1 protein of SARS-CoV-2, Wu et al. [8] employed a novel approach using a Ti₃C₂-MXene nanosheet-modified sensing platform. This 2D material provided a high surface area for ligand immobilization and enhanced the SPR signal, achieving a detection limit of 12 fg/mL. While this represents an advanced application, for routine veterinary diagnostics, a simpler approach is often sufficient. For instance, the capture of antibodies via protein A or protein G is a robust method for analyzing polyclonal sera, as it ensures uniform orientation of the antibody's Fab regions toward the analyte [1, 5]. This is particularly valuable when screening for antibodies against Canine Parvovirus or Feline Leukemia Virus, where the goal is to assess the functional affinity of the humoral response.

A key consideration is the ligand density on the chip surface. For accurate kinetic measurements, the surface capacity (Rmax) should be kept low-typically below 100-200 resonance units (RU) for a 1:1 interaction model. High ligand densities can lead to avidity effects, where a bivalent antibody binds to two adjacent antigen molecules, resulting in an artificially slow dissociation rate and an overestimation of affinity [18]. This is a critical pitfall when working with intact IgG antibodies, which are inherently bivalent. The work by Nguyen et al. [18] on bivalent analyte binding models provides a rigorous framework for addressing this issue. They demonstrated that for a broadly neutralizing HIV-1 mAb binding to gp120, the standard 1:1 Langmuir model was inadequate, and a bivalent model was required. Their identifiability analysis revealed that the second dissociation rate (kd2) was often non-identifiable under standard experimental designs, necessitating an extended dissociation phase to reliably estimate all parameters. This is directly relevant to veterinary applications, such as characterizing the neutralizing antibody response against Foot and Mouth Disease Virus, where avidity can play a significant role in protection.

Analyte Preparation and Injection Protocols

The preparation of the analyte-whether it is a purified monoclonal antibody, a polyclonal serum sample, or a viral antigen-is equally critical. For kinetic analysis, a series of analyte concentrations spanning at least two orders of magnitude around the expected KD is required. For high-affinity interactions (KD < 1 nM), this often means working with concentrations in the low nanomolar to picomolar range. The injection protocol must include a sufficient association phase (typically 120-300 seconds) to allow the binding curve to approach equilibrium, and a dissociation phase (300-600 seconds or longer) to accurately capture the off-rate [16]. For very high-affinity antibodies, such as those elicited against Rabies Lyssavirus glycoprotein, the dissociation phase may need to be extended to 30 minutes or more to obtain a reliable kd value.

A major challenge in viral serology is the analysis of native biomarkers from complex biological matrices. Jucknischke et al. [17] described a method for determining the kinetics of native neurofilament light chain (NFL) from cerebrospinal fluid and sera, which is directly translatable to viral antigens. They employed a target-enrichment step using a primary antibody to capture the native antigen from the matrix, followed by a secondary detection antibody. This sandwich assay format, while more complex, allows for the accurate determination of kinetic constants for native viral antigens that may be present at very low concentrations (pM range) in serum or tissue homogenates. This is particularly relevant for detecting antigens of African Swine Fever Virus or Classical Swine Fever Virus in subclinically infected animals.

The issue of non-specific binding (NSB) cannot be overstated. Serum, plasma, and tissue culture supernatants contain a myriad of proteins that can bind non-specifically to the sensor chip surface, generating a false-positive signal. The protocol must include rigorous controls. The gold standard is the use of a reference flow cell, which is treated identically to the active flow cell but with an irrelevant protein (e.g., bovine serum albumin) immobilized instead of the viral antigen. The signal from the reference cell is subtracted from the active cell signal to correct for bulk refractive index changes and NSB [9, 15]. For particularly problematic samples, additional steps such as serum dialysis, IgG purification, or the use of a high-ionic-strength running buffer (e.g., 1 M NaCl) can be employed to reduce NSB [9]. In the context of veterinary diagnostics, where samples may come from a wide range of species with varying immunoglobulin profiles, these controls are essential for obtaining reliable data.

Kinetic Modeling and Data Analysis

The final step in the protocol is the fitting of the processed sensorgrams to an appropriate kinetic model. While the 1:1 Langmuir binding model is the default for simple interactions, it is often insufficient for viral antigen-antibody systems. The bivalent analyte model, as discussed, is necessary when using intact IgG antibodies [18]. Furthermore, the presence of heterogeneity in the analyte (e.g., polyclonal sera) or the ligand (e.g., a mixture of viral epitopes) can necessitate the use of a two-state reaction model or a heterogeneous ligand model. The choice of model should be guided by the residual plot and the chi-squared value of the fit.

The comparative study by Yang et al. [16] across four biosensor platforms (Biacore T100, ProteOn XPR36, IBIS MX96, and Octet RED384) provides a valuable framework for protocol validation. They demonstrated that with careful optimization of capture density and analyte concentration, all platforms could yield comparable kinetic data for high-affinity mAbs against PCSK9. This is reassuring for veterinary laboratories that may have access to different SPR instruments. However, the study also highlighted that the BLI-based Octet system is more prone to mass transport limitations, requiring even lower ligand densities (e.g., <0.6 nm shift) to achieve accurate results [20]. For the analysis of antibodies against White Spot Syndrome Virus in shrimp, where sample volumes are often limited, the high-throughput capability of the Octet or the IBIS MX96 may be advantageous, provided that the protocol is rigorously optimized.

In summary, the experimental design for SPR-based kinetic analysis of viral antigen-antibody interactions is a systematic process that integrates surface chemistry, ligand immobilization, analyte preparation, and advanced data modeling. The protocol must be tailored to the specific viral system and the biological question at hand, with careful attention to the pitfalls of avidity, non-specific binding, and mass transport. Only through such rigorous design can the kinetic parameters obtained be truly reflective of the in vivo immune response and serve as reliable guides for vaccine development, therapeutic antibody selection, and disease diagnosis.

Molecular Mechanisms of Antigen-Antibody Binding Kinetics: Affinity, Avidity, and Conformational Stability

The fundamental biological interaction between an antigenic epitope and its cognate antibody paratope represents a paradigm of molecular recognition governed by precise physicochemical principles. Surface plasmon resonance (SPR) has emerged as the gold-standard technology for dissecting these interactions in real-time, providing a quantitative framework for understanding affinity, avidity, and the conformational stability that underpins effective immune recognition [5, 16]. For the veterinary clinical pathologist, the ability to precisely characterize these parameters is not merely an academic exercise-it is central to vaccine efficacy assessment, therapeutic antibody development, and the elucidation of protective immunity against viral pathogens. This section delineates the molecular mechanisms that govern antigen-antibody binding kinetics, with particular emphasis on how SPR-based analyses illuminate the thermodynamic and structural determinants of immunological specificity.

The Thermodynamic Landscape of Affinity: Intrinsic Binding Energy and Kinetic Rate Constants

Affinity, at its most fundamental level, refers to the intrinsic strength of the monovalent interaction between a single antigen-binding site (Fab region) and its corresponding epitope. The equilibrium dissociation constant (KD) is the quantitative expression of this relationship, defined as the ratio of the dissociation rate constant (kd, or koff) to the association rate constant (ka, or kon) [6, 23]. A lower KD value indicates higher affinity, reflecting a greater proportion of bound complex at equilibrium. The association rate constant (ka) describes the frequency of productive collisions between antibody and antigen, which is influenced by diffusion rates, molecular orientation, and the electrostatic steering effects that guide the paratope into the epitope binding pocket. The dissociation rate constant (kd) is arguably the more clinically relevant parameter, as it defines the residence time of the antibody-antigen complex-the duration for which the antibody remains bound to its target. In SPR experiments, these rate constants are derived directly from the sensorgram, where the slope of the association phase yields ka information, and the decay of the dissociation phase provides kd data [2, 3].

High-affinity antibodies are characterized by slow dissociation rates (low kd) and moderate-to-fast association rates (high ka). For example, in a study of inactivated poliovirus vaccine strains, SPR revealed remarkably high-affinity interactions between monoclonal antibodies and Sabin strain type 1 poliovirus inactivated with formaldehyde, yielding a KD of 1.39 × 10⁻¹¹ M [1]. Similarly, polyclonal antibodies directed against Sabin strain type 2 poliovirus exhibited a KD of 1.04 × 10⁻¹¹ M when the virus was inactivated with β-propiolactone [1]. These picomolar affinities are indicative of exceptionally stable immune complexes, critical for effective viral neutralization. The retention of such high-affinity binding after inactivation processes underscores that the D-antigen-the protective immunogenic form of the viral capsid-maintains its conformational integrity [1]. This observation is of paramount importance for vaccine development, as it confirms that the inactivated virus retains the epitope architecture necessary to elicit a protective antibody response.

The relationship between antibody affinity and functional activity-particularly virus neutralization-has been elegantly demonstrated in influenza vaccine studies. Using SPR to profile polyclonal serum antibodies from individuals vaccinated with H5N1 influenza vaccines, investigators found that the dissociation rates (kd) against the hemagglutinin HA1 domain were significantly slower (indicating higher affinity) in individuals who had received a heterologous prime-boost regimen compared to those who had not [3]. Critically, strong inverse correlations were observed between these SPR-derived dissociation off-rates and virus neutralization titers against both homologous and heterologous H5N1 clades [2, 3]. This finding establishes that antibody affinity for the HA1 domain-but not the HA2 domain-is the key kinetic determinant of protective immunity. The mechanistic basis for this lies in the functional architecture of hemagglutinin: HA1 contains the receptor-binding site and is the primary target of neutralizing antibodies, whereas HA2 is more conserved but less accessible [2, 3]. These insights have direct implications for vaccine design, as they suggest that vaccine strategies must prioritize the induction of high-affinity antibodies targeting the HA1 domain to achieve broad cross-clade neutralization.

Avidity: The Multivalent Enhancement of Functional Binding Strength

While affinity describes the intrinsic monovalent interaction, avidity-also termed functional affinity-encompasses the total binding strength of a multivalent antibody (such as the bivalent IgG molecule) when it interacts with a multivalent antigen. This is a phenomenon of extraordinary biological significance, particularly in the context of viral pathogens that display repetitive, closely spaced epitopes on their surfaces [4, 18]. Avidity arises from the ability of a single antibody molecule to engage two or more antigen binding sites simultaneously, dramatically increasing the overall stability of the immune complex. The enhancement is not merely additive; it can be multiplicative, as the dissociation of one Fab arm from its epitope is kinetically disfavored when the second Fab arm remains bound, effectively tethering the antibody to the antigen surface.

In SPR experiments, avidity effects must be carefully controlled for, or alternatively, exploited to gain mechanistic insight. When antibodies are flowed as analytes over antigen-coated surfaces, the bivalent nature of IgG can lead to a phenomenon where one antibody molecule binds to two adjacent immobilized antigens [18]. This bivalent binding produces sensorgrams that deviate significantly from a simple 1:1 Langmuir binding model, exhibiting slower apparent dissociation rates due to the rebinding effect. Nguyen et al. [18] have rigorously addressed this issue by developing a bivalent analyte binding model that accounts for both monovalent and bivalent binding events. Their work on HIV-1 broadly neutralizing antibodies binding to gp120 envelope glycoprotein demonstrated that when the dissociation phase was extended sufficiently, the parameters governing bivalent binding-including the rate constants for both Fab-arm interactions-could be reliably estimated. This methodological advancement is critical for high-throughput SPR platforms where regeneration between cycles is not feasible, enabling accurate kinetic analysis even in the presence of avidity artifacts [18].

The biological relevance of avidity is profound when considering viral pathogens that present multimeric surface antigens. For instance, viruses such as Avian Influenza Virus display trimeric hemagglutinin spikes, creating a high-density array of identical epitopes that can be cross-linked by bivalent IgG. Similarly, the capsid proteins of non-enveloped viruses like Infectious Bursal Disease Virus or Foot and Mouth Disease Virus present regularly arranged epitopes on their icosahedral surfaces, ideal platforms for high-avidity interactions. In aquatic virology, the enveloped White Spot Syndrome Virus expresses multiple copies of envelope proteins that serve as targets for neutralizing antibodies; the avidity of these interactions directly correlates with protective immunity in shrimp. The ability of SPR to quantify these multivalent interactions provides the clinical pathologist with a powerful tool for evaluating vaccine-induced antibody quality.

Yang et al. [4] have developed an innovative nanogel-based SPR approach to specifically evaluate multivalent protein binding. By incorporating pNIPAm-co-AAc nanogels with multivalent binding moieties (such as PD-1 antigen or biocytin), they created a system where SPR signals are amplified by the multivalent interactions. This method enabled the detection of PD-1 antibody down to 10 nM, demonstrating that multivalent binding enhances both sensitivity and specificity [4]. The clinical relevance extends beyond therapeutic antibodies to autoimmune disease monitoring: anti-dsDNA antibodies in systemic lupus erythematosus (SLE) are often of moderate affinity when measured by conventional assays, but SPR reveals that only high-avidity antibodies are associated with lupus nephritis [22]. Nagant et al. [22] demonstrated that fibre-optic SPR (FO-SPR) could distinguish SLE patients with renal involvement based on kinetic profiles, with high-avidity anti-dsDNA antibodies showing significantly higher association rates and maximal binding responses. The area under the ROC curve for SPR-derived affinity parameters was 0.82 (P = 0.006), outperforming standard chemiluminescent assays for discriminating nephritis from non-nephritis SLE [22].

Conformational Stability: The Structural Integrity of Epitopes Underlying Kinetic Performance

The binding kinetics of an antibody-antigen interaction are exquisitely sensitive to the conformational state of both the epitope and the paratope. Conformational stability refers to the ability of a protein-whether antigen or antibody-to maintain its native three-dimensional structure under various environmental conditions. In the context of viral diagnostics and vaccine development, conformational stability is paramount: an antibody raised against a native viral epitope may fail to bind if the epitope is denatured, aggregated, or conformationally altered [1, 23]. SPR provides a unique window into these structural phenomena because the technique monitors binding in real-time without requiring labels that might themselves disrupt conformation.

The impact of conformational changes on antigen-antibody binding was dramatically illustrated in studies of bovine serum albumin (BSA) subjected to ultra-high pressure (UHP) and moderate heat treatment. Wang et al. [23] demonstrated that as pressure increased from 0.1 MPa to 600 MPa, the equilibrium dissociation constant (KD) for BSA-IgG binding increased from 3.15 × 10⁻⁷ M to 66.42 × 10⁻⁷ M-a more than 20-fold reduction in affinity. This loss of binding was attributed to pressure-induced breakage of disulfide bonds, protein unfolding, and aggregation, which disrupted the conformational epitopes recognized by the antibody [23]. Such findings have direct implications for food safety and allergenicity assessment, as UHP processing is used in the food industry to reduce allergenic potential. For the diagnostic pathologist, these results underscore that antigen processing conditions must be carefully controlled to preserve epitope integrity for accurate immunoassay performance.

In viral vaccine production, maintaining the conformational stability of protective epitopes is a critical quality control parameter. Gnedenko et al. [1] used SPR to verify that the D-antigen of poliovirus-the protective immunogenic form-remained intact after inactivation with either β-propiolactone or formaldehyde. The high-affinity interactions observed (KD values in the 10⁻¹¹ M range) confirmed that the capsid had not undergone deleterious conformational changes during the inactivation process [1]. Similarly, for SARS-CoV-2, the spike protein's receptor-binding domain (RBD) and S1 subunit must maintain their native conformation for accurate serological testing. The development of sandwich-structured SPR biosensors using Ti₃C₂-MXene nanosheets and polydopamine-Ag nanoparticle conjugates achieved a detection limit of 12 fg/mL for SARS-CoV-2 spike S1 protein, with the high sensitivity dependent on the conformational integrity of the immobilized antigen [8]. Any denaturation of the spike protein would dramatically reduce the binding signal, emphasizing that antigen quality is the limiting factor in SPR-based viral detection.

The role of glycosylation in conformational stability and subsequent antibody binding kinetics has been addressed using SPR. Wong et al. [14] compared the binding kinetics of native IgG4, deglycosylated IgG4, and F(ab')₂ fragments to their antigen. The equilibrium binding constants were remarkably similar: native IgG4 exhibited a KD of 1.81 × 10⁻⁹ M, deglycosylated IgG4 showed 1.96 × 10⁻⁹ M, and the F(ab')₂ fragment demonstrated 5.79 × 10⁻¹⁰ M [14]. These data indicate that the Fc glycan does not contribute to antigen binding and that the antigen-binding conformation of the Fab region is stable even in the absence of glycosylation. However, the clinical relevance of Fc glycosylation lies in effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation, rather than in the initial binding event [14]. For the clinical pathologist, this means that SPR-based affinity measurements can be performed on deglycosylated antibodies without compromising the accuracy of ka and kd determination, simplifying experimental design.

Seasonal and pandemic influenza viruses present a particular challenge for conformational stability due to the high mutation rate of the hemagglutinin gene. The emergence of antigenic drift variants is driven by amino acid substitutions that alter the conformation of antibody-binding sites. Studies using SPR have shown that antibodies elicited by clade 1 H5N1 vaccines exhibit significantly reduced binding affinity (faster dissociation rates) against heterologous clade 2.1 strains [2, 3]. This loss of binding is a direct consequence of conformational changes in the HA1 domain-alterations in the surface loops that constitute the receptor-binding site and nearby antibody epitopes. The ability of adjuvants such as MF59 to promote antibody affinity maturation, resulting in slower dissociation rates against both homologous and heterologous HA proteins, has been attributed to their capacity to enhance germinal center reactions and select for B cells producing antibodies that can accommodate minor conformational variations [3]. This mechanistic understanding, derived from SPR kinetics, has guided the development of broadly protective pandemic influenza vaccines.

Epitope Conformation and the Challenge of Non-Specific Binding

One of the persistent challenges in SPR-based analysis of viral antigen-antibody interactions is distinguishing specific, conformation-dependent binding from non-specific adsorption. Non-specific binding (NSB) can arise from hydrophobic interactions, electrostatic attraction to the sensor chip surface, or recognition of denatured protein contaminants [9, 15]. This is particularly problematic when using complex biological matrices such as serum, cerebrospinal fluid, or tissue homogenates from infected animals. Visentin et al. [9] developed a method to overcome NSB in human serum for anti-HLA antibody detection by employing a non-cognate target protein-structurally similar to the cognate antigen-in a separate binding cycle. Subtracting the NSB signal from the total binding signal allowed accurate determination of both active antibody concentration and affinity, even at concentrations near the 0.5-1 nM quantification limit [9]. This approach is directly applicable to veterinary serology, where serum samples from animals infected with viruses such as Bovine Viral Diarrhea Virus or Classical Swine Fever Virus often contain high levels of background immunoglobulins.

The problem of NSB is compounded when using peptide microarrays or artificial epitopes. Nogues et al. [15] demonstrated that careful optimization of self-assembling monolayer (SAM) chemistry could reduce NSB sufficiently to allow accurate kinetic and thermodynamic analysis of antibody binding to the autoantigen GAD65. Their approach eliminated the need for problematic background subtraction and enabled the application of complex interaction models beyond simple 1:1 Langmuir binding [15]. For viral diagnostics, this means that SPR can be used to characterize antibody responses to linear peptide epitopes (e.g., from Avian Leukosis Virus or Porcine Reproductive and Respiratory Syndrome Virus) with high confidence, provided the sensor surface is properly engineered.

Thermodynamic Signatures: Enthalpy and Entropy Compensation in Binding Kinetics

Beyond the kinetic rate constants, SPR can provide thermodynamic information when experiments are conducted at multiple temperatures. By measuring the temperature dependence of the equilibrium dissociation constant (KD), the van't Hoff equation yields changes in enthalpy (ΔH) and entropy (ΔS) associated with binding [15]. These thermodynamic signatures offer insights into the molecular forces driving the interaction. High-affinity antibody-antigen interactions typically exhibit negative (favorable) ΔH values, reflecting the formation of hydrogen bonds, van der Waals interactions, and electrostatic contacts at the binding interface. However, these favorable enthalpy changes are often partially offset by unfavorable entropy changes, as the binding event restricts the conformational freedom of both the antibody CDR loops and the antigen epitope-a phenomenon known as enthalpy-entropy compensation.

In the context of viral antigen-antibody binding, thermodynamic analysis has revealed that antibodies can achieve high affinity through different combinations of ka and kd, with distinct thermodynamic underpinnings. Antibodies that exhibit extremely slow dissociation rates (very low kd) often possess deep binding pockets that envelop the epitope, creating extensive van der Waals contacts that are enthalpically favorable. Conversely, antibodies with very fast association rates (high ka) may utilize electrostatic steering-where complementary charges on the antibody and antigen surfaces guide the molecules into a productive binding orientation. These thermodynamic distinctions have practical implications for vaccine design: antigens that elicit antibodies with favorable enthalpy-driven binding (low kd) are more likely to provide durable protection because the antibody-antigen complex has a long residence time.

The temperature dependence of binding kinetics also has implications for diagnostic test performance. Cold-water fish pathogens such as Infectious Hematopoietic Necrosis Virus or Viral Hemorrhagic Septicemia Virus infect hosts at low environmental temperatures (typically 10-15°C), where molecular diffusion is slowed and protein dynamics are altered. SPR experiments performed at physiologically relevant temperatures for these species would likely reveal different kinetic parameters than those conducted at standard laboratory temperatures (25°C). Similarly, for febrile responses in mammals (e.g., 39-41°C in pigs infected with African Swine Fever Virus), the binding thermodynamics of antibody-antigen interactions may shift, potentially affecting diagnostic assay sensitivity. These considerations underscore the importance of conducting SPR experiments under temperature conditions that mimic the physiological environment of the target species.

The Clinical Pathologist's Perspective: Translating Kinetics into Diagnostics and Therapeutics

For the practicing veterinary clinical pathologist, the molecular mechanisms of antigen-antibody binding kinetics are not abstract concepts-they are the biophysical basis for diagnostic test performance and therapeutic efficacy. The affinity of an antibody for its target antigen determines the limit of detection in immunoassays, the specificity of serological tests, and the potency of neutralizing antibodies. In the context of SPR-based diagnostics, kinetic parameters can distinguish between early and late stages of infection, predict disease severity, and monitor vaccine responses.

The case of anti-dsDNA antibodies in lupus nephritis provides a paradigm for how kinetic profiling can enhance diagnostic accuracy. Conventional anti-dsDNA assays detect both high-affinity pathogenic antibodies and low-affinity non-pathogenic antibodies, leading to false positives and poor correlation with disease activity. SPR, by contrast, selectively identifies the high-affinity, pathogenic subset, improving the discrimination between active renal disease and quiescent SLE [22]. For veterinary medicine, analogous situations exist: antibodies directed against Feline Immunodeficiency Virus or Equine Infectious Anemia Virus may be present in serum but vary in affinity depending on the stage of infection. SPR-based kinetic profiling could provide a more nuanced assessment of disease status than endpoint titer measurements alone.

In vaccine development, the ability of SPR to measure antibody affinity maturation-the progressive increase in affinity that occurs during the germinal center reaction-provides a quantitative endpoint for evaluating vaccine immunogenicity. Adjuvants such as MF59 have been shown to promote affinity maturation, as evidenced by slower dissociation rates in SPR assays [3]. Similarly, replicating viral vectors (e.g., Ad4-H5) prime the immune system to generate higher-affinity antibodies upon subsequent booster immunization [2]. These findings have direct relevance to veterinary vaccine development for pathogens such as Infectious Bronchitis Virus in poultry or Porcine Circovirus 2 in swine, where durable, high-affinity antibody responses are essential for herd immunity.

Finally, the conformational stability of viral antigens-whether native, inactivated, or recombinant-is a critical quality attribute for both vaccines and diagnostic reagents. SPR provides a rapid, label-free method to verify that antigenic epitopes maintain their native conformation after manufacturing, storage, or formulation. For aquatic viruses such as Koi Herpesvirus or Red Sea Bream Iridovirus, where diagnostic antigen availability may be limited, ensuring conformational integrity becomes even more critical. The clinical pathologist must therefore understand not only how to interpret SPR-derived kinetic constants but also how experimental conditions-temperature, pH, buffer composition, and antigen preparation-influence the conformational state of the proteins under study.

Clinical Application: Vaccine-Induced Antibody Affinity Maturation and Cross-Protective Immunity

The deployment of efficacious vaccines remains the cornerstone of veterinary and human pandemic preparedness, yet the mere induction of high-titer antibody responses is an incomplete metric of protective immunity. A paradigm shift in vaccinology has emerged, recognizing that the functional quality of the humoral response-specifically, the affinity maturation of polyclonal antibodies and their resultant cross-reactivity against antigenically divergent strains-is paramount. Surface plasmon resonance (SPR) has proven to be an indispensable, label-free platform for dissecting these kinetic parameters in real time, providing a biophysical bridge between vaccine formulation and clinical protection. This section delineates the mechanistic underpinnings of how SPR-based kinetic profiling informs the development of vaccines that elicit broadly neutralizing antibodies, with a particular focus on prime-boost strategies and the critical role of the germinal center reaction.

The Kinetic Basis of Affinity Maturation: From (k_d) to Broad Protection

Traditional serological assays, such as hemagglutination inhibition (HI) or enzyme-linked immunosorbent assay (ELISA), primarily report endpoint titers but fail to distinguish between low-affinity, polyreactive antibodies and high-affinity, somatically hypermutated immunoglobulins. SPR overcomes this limitation by providing real-time measurements of association rates ((k_a)) and, more critically, dissociation rates ((k_d)). The equilibrium dissociation constant ((K_D = k_d/k_a)) is the classical metric of affinity, but in the context of vaccine-induced immunity, the dissociation rate has emerged as a superior surrogate for functional antibody quality. A slower off-rate (lower (k_d)) indicates that the antibody-antigen complex is more stable, a property that correlates strongly with viral neutralization capacity and in vivo protection.

This principle was elegantly demonstrated in clinical trials evaluating H5N1 pandemic influenza vaccines. Khurana et al. utilized SPR to analyze sera from individuals who received a heterologous prime-boost regimen comprising an MF59-adjuvanted H5N3 vaccine (clade 0) followed years later by an MF59-adjuvanted H5N1 (clade 1) booster. Compared to unprimed individuals who received two doses of the H5N1 vaccine, the primed group exhibited significantly slower dissociation rates (i.e., higher affinity) of polyclonal antibodies against the HA1 domain of the hemagglutinin protein [3]. Critically, these kinetic parameters-specifically the (k_d) values-showed a strong inverse correlation with virus neutralization titers against not only the homologous H5N1 strain but also against heterologous clade 2 viruses [3]. This finding positions SPR as a tool capable of predicting cross-clade neutralization breadth, a feat unattainable by endpoint titer measurements alone. The same group later confirmed this paradigm using a replication-competent adenovirus serotype 4 (Ad4-H5) vector prime followed by a subunit H5N1 boost. Again, SPR revealed that the Ad4-H5 priming dramatically enhanced the dissociation rates of HA1-specific antibodies, and these slower off-rates correlated with superior neutralization of a panel of heterologous H5N1 clade 2 strains [2]. These data underscore that the magnitude of the memory B cell pool is less relevant than the affinity of its B cell receptors, a quality that SPR can precisely quantify.

Mechanistic Insights into Prime-Boost Strategies and Germinal Center Reactivation

Why does heterologous priming exert such a profound effect on antibody affinity? The answer lies in the B cell germinal center (GC) reaction. Primary vaccination establishes a pool of memory B cells, many of which express B cell receptors with moderate affinity. Upon re-exposure to antigen-even a variant antigen-these memory B cells are recruited into secondary GCs where they undergo iterative rounds of somatic hypermutation and affinity-based selection. The result is the emergence of plasma cells secreting antibodies with markedly improved (K_D) values, particularly driven by a reduction in (k_d). SPR provides the only direct, real-time window into this process by analyzing polyclonal sera.

The data from the H5N1 prime-boost studies are illuminating. In the MF59-adjuvanted trial, the SPR-derived off-rates for HA1-specific antibodies in primed individuals were significantly lower (indicating higher affinity) than those in unprimed individuals, even after the unprimed group received a second vaccine dose [3]. This suggests that the initial priming event, particularly when administered with an oil-in-water adjuvant like MF59, establishes a memory B cell repertoire that is qualitatively superior. The booster vaccination then selectively expands those B cell clones with the highest affinity for the conserved epitopes of HA1. Importantly, the correlation between (k_d) and neutralization was specific to the HA1 domain, not the more conserved HA2 stem region [3]. This finding highlights a key nuance: while broadly neutralizing antibodies targeting HA2 exist, the cross-protective immunity observed in these trials was driven by affinity-matured antibodies against the globular head domain (HA1), which is typically considered more variable. SPR thus revealed that vaccine-induced affinity maturation can overcome antigenic drift within the HA1 domain itself, a concept with profound implications for the development of "universal" influenza vaccines for both humans and animals, such as against Avian Influenza Virus in poultry.

Adjuvant Modulation of Antibody Kinetics and the Role of Avidity

The choice of adjuvant is not merely a matter of enhancing immunogenicity; it fundamentally shapes the kinetic quality of the antibody response. The MF59 adjuvant, as shown in the H5N1 studies, promoted a more rapid and profound affinity maturation compared to unadjuvanted vaccines [3]. SPR analysis of sera from the MF59-primed groups revealed that a single booster dose elicited antibodies with (k_d) values that were comparable to, or even superior to, those achieved after two doses of vaccine in unprimed subjects. This kinetic advantage translated into a significant expansion of cross-clade neutralization. From a veterinary clinical pathology perspective, this is directly relevant to vaccine development for livestock and companion animals. For instance, adjuvanted vaccines against Porcine Reproductive and Respiratory Syndrome Virus or Infectious Bronchitis Virus could be screened using SPR to identify formulations that promote the slowest off-rates against heterologous field strains, thereby predicting cross-protection prior to costly challenge studies.

Furthermore, when analyzing polyclonal sera, the phenomenon of avidity-the synergistic binding of bivalent IgG antibodies-must be considered. In a standard SPR format where antigen is immobilized on the chip, flowing polyclonal IgG can bind bivalently, leading to an apparent affinity that is higher than the intrinsic monovalent affinity. Nguyen et al. have developed rigorous bivalent analyte models to account for this, using ordinary differential equations to deconvolute the contributions of monovalent and bivalent binding [18]. This is critical for vaccine studies because the avidity effect can mask the true intrinsic affinity of the antibody. A well-designed SPR assay, with careful control of antigen density to minimize avidity artifacts, can distinguish whether a vaccine induces genuinely high-affinity monovalent binding or relies on avidity-enhanced binding. The former is typically a hallmark of superior GC-derived antibodies. For example, in surface-immobilized formats, the use of a low-density antigen surface can force monovalent binding, allowing for the accurate determination of intrinsic (K_D) values, as demonstrated in high-throughput screening platforms for therapeutic monoclonal antibodies [16, 24].

Cross-Protective Immunity in the Face of Antigenic Variation: A Veterinary Perspective

The principles derived from human influenza vaccine trials are directly translatable to veterinary medicine, where antigenic drift and shift present constant challenges. The WOAH and FAO have long emphasized the need for vaccines that provide broad protection against rapidly evolving pathogens such as Foot and Mouth Disease Virus, Classical Swine Fever Virus, and Newcastle Disease Virus. In each case, the ability of a vaccine to induce antibodies that bind with high affinity to conserved epitopes-demonstrated by slow (k_d) values in SPR assays-is a strong predictor of cross-protective immunity.

Consider the example of Infectious Bursal Disease Virus (IBDV) in poultry, where antigenic variants have emerged that evade immunity induced by classic vaccine strains. An SPR-based approach could be used to screen the polyclonal sera from chickens vaccinated with variant-specific or broadly protective vaccines. By measuring the binding kinetics to VP2 capsid proteins from different IBDV serotypes and variants, one can quantify the degree of kinetic cross-reactivity. A vaccine that induces a polyclonal response with low (k_d) against multiple VP2 variants would be predicted to provide superior field protection. Similarly, for Swine Influenza A Virus in pigs, the correlation between SPR-derived off-rates for HA1-specific antibodies and cross-neutralization titers, as shown in the human H5N1 trials [2, 3], provides a robust template for evaluating novel swine influenza vaccines.

Real-World Implementation: High-Throughput and Portable SPR Platforms

To translate these kinetic insights into routine vaccine development and quality control, the field has moved toward high-throughput SPR platforms. Instruments capable of 384 interaction analyses per week, such as those using the Brevibacillus expression system for rapid antibody production and screening, are now available [11]. These systems enable the parallel kinetic characterization of hundreds of vaccine-induced antibody clones or polyclonal sera against multiple antigen variants. The utility of such platforms for epitope binning and identifying antibodies with broad reactivity has been demonstrated in therapeutic monoclonal antibody discovery [24]. In a vaccine development pipeline, this allows researchers to rapidly identify vaccine formulations that consistently produce high-affinity, cross-reactive antibodies.

Beyond the laboratory, portable SPR biosensors are emerging as point-of-care tools for assessing vaccine efficacy in the field. The development of fiber-optic SPR (FO-SPR) sensors, as demonstrated for anti-dsDNA antibody profiling in lupus [22], could be adapted for veterinary use. Imagine a handheld device that, using a drop of serum from a vaccinated chicken or pig, can provide an immediate readout of the (k_d) for antibodies binding to a panel of viral antigens. This would allow veterinarians and producers to monitor herd immunity in real time, identifying waning protection or the emergence of escape variants long before clinical disease appears. Such technology, built on the same principles as the electrochemical SPR sensors used for H5N1 detection [13] or the localized SPR (LSPR) nanoparticle layers for label-free antigen detection [7], is becoming increasingly feasible.

Addressing the Challenge of Non-Specific Binding in Complex Matrices

A persistent limitation in applying SPR to vaccine serology is the presence of non-specific binding (NSB) from other serum proteins. This is particularly problematic when analyzing polyclonal sera from veterinary species, where the matrix can be highly variable. Visentin et al. developed a robust method to overcome this by using a non-cognate target (a structurally similar but irrelevant protein) to subtract the NSB contribution [9]. This approach, validated for anti-HLA antibodies in human serum, is directly applicable to veterinary vaccine studies. By immobilizing both the target viral antigen and a control protein on separate flow cells, the specific binding signal can be accurately isolated, even at low antibody concentrations (0.5-1 nM range). This methodological refinement ensures that the kinetic parameters ((k_a), (k_d), (K_D)) derived from SPR assays are truly reflective of the vaccine-induced antibody response and not confounded by matrix effects. This rigor is essential when comparing responses across different vaccine platforms, adjuvants, or animal species.

The Glycosylation Connection: Does It Affect Affinity?

Monoclonal antibody therapeutics have demonstrated that the Fc glycosylation pattern does not significantly alter antigen-binding kinetics, as measured by SPR. Wong et al. showed that the (K_D) values for a deglycosylated IgG4 antibody were nearly identical to its native, glycosylated counterpart (1.96 × 10⁻⁹ M vs. 1.81 × 10⁻⁹ M, respectively) [14]. While this study was performed on a monoclonal antibody, it has implications for vaccine design: the quality of the humoral immune response, in terms of antigen binding, appears to be driven primarily by the structural complementarity of the paratope and epitope, not by post-translational modifications on the antibody Fc. Therefore, SPR-based kinetic analysis of sera directly reflects the success of germinal center selection and somatic hypermutation, independent of any potential alterations in glycosylation pathways induced by different adjuvants or vaccine platforms. This reinforces the use of SPR as a primary tool for assessing the functional quality of vaccine-elicited antibodies.

Performance Metrics: Correlation of SPR-Derived Kinetic Parameters with Virus Neutralization and Protective Efficacy

The translation of surface plasmon resonance (SPR)-derived kinetic parameters into meaningful correlates of protective immunity represents one of the most clinically consequential applications of this technology in veterinary and human virology. While SPR has long been celebrated for its capacity to provide exquisitely precise measurements of association rates (ka), dissociation rates (kd), and equilibrium dissociation constants (KD), the ultimate value of these metrics lies in their ability to predict-or at minimum, to correlate with-functional outcomes such as virus neutralization titers and in vivo protective efficacy. This section provides a comprehensive examination of the evidence base linking SPR-derived kinetic parameters to these critical performance metrics, with particular emphasis on the mechanistic underpinnings that govern these correlations.

The Mechanistic Basis for Kinetic Correlates of Neutralization

The relationship between antibody-antigen binding kinetics and virus neutralization is not merely correlative but is rooted in fundamental principles of immunology and biophysics. Neutralization of viral infectivity requires that antibodies bind to critical epitopes on the viral surface-typically the receptor-binding domains of attachment proteins-with sufficient avidity and, critically, with sufficiently slow dissociation kinetics to prevent the virus from engaging its cellular receptor. The dissociation rate constant (kd) has emerged as the single most informative SPR-derived parameter for predicting neutralizing capacity, a finding that has been replicated across multiple viral systems.

Khurana and colleagues provided landmark evidence for this relationship in their investigation of H5N1 influenza vaccine responses [2, 3]. In a Phase I trial of a replication-competent adenovirus serotype 4 (Ad4)-vectored H5N1 vaccine, these investigators demonstrated that the antigen-antibody complex dissociation rates (kd) of serum polyclonal antibodies against the HA1 domain of hemagglutinin were significantly higher in individuals who received Ad4-H5 priming followed by a subunit boost, compared with those receiving subunit vaccine alone [2]. Critically, strong correlations were observed between these SPR-derived dissociation rates and virus neutralization titers against both homologous (A/Vietnam/1194/2004, clade 1) and heterologous (A/Indonesia-5/2005, clade 2.1) H5N1 strains. The correlation was specific to the HA1 domain; no such relationship was observed for antibodies targeting the HA2 stalk region, underscoring the epitope-specific nature of the kinetic-neutralization relationship.

In a parallel study examining MF59-adjuvanted heterologous prime-boost strategies, the same group demonstrated that the dissociation off-rates of polyclonal sera against HA1 showed strong inverse correlations with virus neutralization titers against H5 vaccine strains and heterologous H5N1 strains [3]. The term "inverse correlation" here is critical: slower dissociation (lower kd values) corresponded to higher neutralizing titers, consistent with the model that antibodies that remain bound to their target epitopes for longer durations are more effective at blocking viral entry. This relationship held true across multiple clades of H5N1, suggesting that the kinetic quality of the antibody response, rather than simply its magnitude, is a key determinant of cross-protective breadth.

Affinity Maturation and the Evolution of Protective Antibody Responses

The SPR platform provides unique insights into the process of affinity maturation-the progressive improvement of antibody affinity that occurs during the course of an immune response or following vaccination. This phenomenon is exquisitely captured by changes in the equilibrium dissociation constant (KD) and, more specifically, by improvements in the dissociation rate constant over time.

Gnedenko and colleagues, in their analysis of inactivated poliovirus vaccine strains, demonstrated that the interaction between polyclonal antibodies and Sabin strain type 2 poliovirus inactivated with β-propiolactone exhibited extraordinarily high affinity, with a KD of 1.04 × 10⁻¹¹ M [1]. Similarly, monoclonal antibodies to Sabin strain type 1 poliovirus interacting with formaldehyde-inactivated virus yielded a KD of 1.39 × 10⁻¹¹ M [1]. These picomolar affinities are characteristic of antibodies that have undergone extensive affinity maturation and are associated with robust neutralizing capacity. The authors noted that the preservation of high-affinity binding following inactivation indicated that the D-antigen-the immunologically relevant conformational epitope-remained structurally intact, a finding with direct implications for vaccine quality control.

The clinical significance of affinity maturation is further illustrated by studies of anti-dsDNA antibodies in systemic lupus erythematosus (SLE), where Nagant and colleagues employed a novel fiber-optic SPR (FO-SPR) biosensor to profile antibody kinetics [22]. Although this work was conducted in an autoimmune context rather than a viral infection, the principles are directly transferable. The investigators found that SLE patients with lupus nephritis (LN) exhibited anti-dsDNA antibodies with significantly higher association rates and lower dissociation constants-i.e., higher affinity-compared with SLE patients without renal involvement [22]. The area under the receiver operating characteristic curve (AUC-ROC) for SPR-derived affinity parameters was 0.82 (P = 0.006), outperforming conventional chemiluminescent immunoassays for discriminating LN from non-nephritis SLE. This study elegantly demonstrates that kinetic parameters can serve as biomarkers of disease severity, a concept that has direct analogs in infectious disease, where high-affinity antibodies are associated with more effective viral clearance and, paradoxically in some contexts, with enhanced immunopathology.

The Role of Avidity and Multivalent Binding in Protective Efficacy

A critical distinction that must be appreciated when interpreting SPR-derived kinetic parameters is the difference between affinity (the intrinsic strength of a single antibody-antigen binding site interaction) and avidity (the overall binding strength resulting from multivalent interactions). This distinction is particularly relevant for viral antigens, which often present multiple identical epitopes in a spatially organized array on the virion surface.

Nguyen and colleagues addressed this complexity through a rigorous mathematical framework for bivalent analyte binding kinetics [18]. Using HIV-1 broadly neutralizing monoclonal antibodies (bNAbs) binding to envelope glycoprotein gp120, these investigators demonstrated that a simple 1:1 Langmuir binding model is often inadequate when antibodies in solution bind to immobilized antigens, because the bivalent nature of IgG antibodies can produce apparent affinity enhancements due to avidity effects. Their identifiability analysis revealed that one of the kinetic parameters (kd2, representing the dissociation rate of the second binding event) could not be reliably estimated under standard experimental designs [18]. Through simulation studies, they determined the optimal length of the dissociation phase required for reliable parameter estimation, providing a methodological framework that is directly applicable to veterinary vaccine evaluation.

The implications of avidity for protective efficacy are profound. Antibodies that can engage in bivalent or multivalent binding to viral surfaces exhibit dramatically slower overall dissociation rates than would be predicted from their monovalent affinity alone. This phenomenon, termed "avidity-driven neutralization," is particularly important for viruses with high epitope density on their surface, such as Avian Influenza Virus and Newcastle Disease Virus. In such systems, SPR assays that employ monomeric antigens may underestimate the functional neutralizing capacity of antibodies, whereas assays that present antigens in a multivalent format-such as virus-like particles or intact virions-may provide more accurate correlates of protection.

Cross-Clade and Heterologous Neutralization: Kinetic Determinants of Breadth

One of the most challenging problems in veterinary vaccinology is the induction of broadly protective immune responses capable of neutralizing diverse viral strains or serotypes. SPR has proven invaluable for dissecting the kinetic basis of cross-reactive neutralization.

The work of Khurana and colleagues on H5N1 influenza is again instructive. Their SPR analyses revealed that the antibody dissociation rates against the HA1 domain-but not the HA2 domain-correlated with neutralization titers against a panel of heterologous clade 2 H5N1 strains [2, 3]. This finding suggests that the kinetic quality of antibodies targeting the variable head region of hemagglutinin is a key determinant of cross-clade neutralization breadth. Importantly, the prime-boost strategies evaluated in these studies (Ad4-H5 priming followed by subunit boost, or MF59-adjuvanted heterologous priming) produced antibodies with significantly slower dissociation rates compared with unprimed vaccination regimens, and these kinetic improvements translated directly into enhanced cross-neutralization [2, 3].

The implications for veterinary pathogens are substantial. For viruses such as Infectious Bursal Disease Virus and its variants, or Bovine Viral Diarrhea Virus with its type 1 and type 2 genotypes, the ability of a vaccine to induce antibodies with slow dissociation rates against conserved epitopes may be the key to achieving broad protection. SPR-based kinetic profiling of post-vaccination sera could serve as a surrogate marker for cross-protective immunity, potentially reducing the need for extensive and costly challenge studies.

Methodological Considerations for Accurate Kinetic-Neutralization Correlations

The reliability of correlations between SPR-derived kinetic parameters and virus neutralization depends critically on experimental design. Several factors must be carefully controlled to ensure that SPR measurements accurately reflect the functional properties of antibodies in solution.

First, the choice of antigen format is paramount. As demonstrated by Jucknischke and colleagues, antibodies that bind with high affinity to recombinant antigens may show no or significantly weakened binding to native antigens [17]. This discrepancy was observed for neurofilament light chain (NFL) as a biomarker, where antibodies that recognized recombinant NFL with high affinity failed to bind native NFL from patient samples [17]. In the context of viral antigens, this means that SPR assays employing recombinant proteins may overestimate or underestimate neutralizing capacity depending on whether the recombinant protein faithfully recapitulates the native conformation of the viral epitope.

Second, the issue of non-specific binding (NSB) in complex matrices such as serum must be addressed. Visentin and colleagues developed a rigorous method for eliminating NSB contributions to SPR signals when measuring anti-HLA antibodies in human serum, demonstrating that serum treatments such as dialysis or IgG purification were insufficient for SPR applications [9]. Their approach, which involved using a non-cognate target structurally similar to the target of interest in a separate binding cycle, enabled precise determination of active antibody concentrations and affinities even at concentrations as low as 0.5-1 nM [9]. This methodology is directly applicable to veterinary serology, where serum from vaccinated or infected animals often contains high levels of non-specific immunoglobulins that can confound SPR measurements.

Third, the choice of biosensor platform can influence the comparability of kinetic parameters. Gnedenko and colleagues directly compared the Biacore X-100 (Cytiva, USA) and the MI-S200D (Inter-Bio, China) SPR instruments and found that association rate constants for IgG antibodies binding to protein A were within one order of magnitude between the two platforms, while dissociation rate constants for IgG1 antibodies were nearly identical [5]. Both devices produced data well-described by a simple 1:1 Langmuir binding model [5]. This comparability is encouraging for multi-site studies and for the transfer of kinetic assays between laboratories, but it also underscores the need for standardized protocols and data analysis pipelines to ensure that kinetic-neutralization correlations are robust and reproducible.

From Kinetic Parameters to Protective Thresholds: The Path to Correlates of Protection

The ultimate goal of correlating SPR-derived kinetic parameters with virus neutralization is the establishment of quantitative correlates of protection-threshold values of ka, kd, or KD that predict whether an individual or population will be protected from infection or disease following vaccination or natural exposure.

The work of Khurana and colleagues provides a template for how such correlates might be established. By demonstrating that antibody dissociation rates against HA1 correlate with neutralization titers across multiple H5N1 clades [2, 3], these investigators identified a kinetic parameter that could serve as a surrogate for protective immunity. If similar relationships can be established for veterinary pathogens, SPR could become a powerful tool for vaccine evaluation and licensure.

For example, in the context of Classical Swine Fever Virus or African Swine Fever Virus, where traditional neutralization assays are technically challenging or require high-containment facilities, SPR-based kinetic profiling of post-vaccination sera could provide a safer, faster, and more quantitative alternative for assessing vaccine immunogenicity. Similarly, for aquatic viruses such as Infectious Salmon Anemia Virus or Viral Hemorrhagic Septicemia Virus, where cell culture-based neutralization assays may be limited by the availability of permissive cell lines, SPR could offer a robust platform for evaluating antibody quality.

The establishment of kinetic correlates of protection will require systematic studies that integrate SPR measurements with in vivo challenge experiments in target species. Such studies should aim to define the minimal antibody affinity (or maximal dissociation rate) required for protection, accounting for variables such as viral dose, route of exposure, and the immunological history of the host. The World Organisation for Animal Health (WOAH) has recognized the potential of such approaches for vaccine evaluation, and ongoing efforts to standardize SPR protocols for veterinary applications are likely to accelerate the adoption of these methods in regulatory settings.

Emerging Technologies and Future Directions

The field of SPR-based kinetic analysis is evolving rapidly, with new technologies offering enhanced throughput, sensitivity, and multiplexing capabilities that will facilitate the establishment of kinetic-neutralization correlations on a larger scale.

Matsunaga and colleagues developed a high-throughput SPR analysis system named "BreviA" that enables the process from antibody gene transformation to 384 interaction analyses within a single week [11]. This system, which employs the Brevibacillus expression system for rapid antibody production and screening, was used to identify mutants of an anti-PD-1 antibody with >100-fold increased affinity for mouse PD-1 [11]. Applied to viral antigens, such high-throughput platforms could enable the rapid identification of monoclonal antibodies with optimal kinetic profiles for neutralization, accelerating the development of therapeutic antibodies and diagnostic reagents.

Matharu and colleagues demonstrated the power of array-based SPR for high-throughput epitope binning and affinity characterization of monoclonal antibodies [24]. By integrating epitope binning results with binding kinetics and sequence analysis, these investigators were able to select high-affinity antibodies representing diverse epitopes and sequence families [24]. This approach is directly applicable to the discovery of broadly neutralizing antibodies against viruses such as Porcine Reproductive and Respiratory Syndrome Virus or Canine Distemper Virus, where epitope diversity is critical for overcoming viral immune evasion.

The development of portable SPR biosensors, as described by Jodaylami and colleagues for SARS-CoV-2 antibody detection [19], raises the possibility of point-of-care kinetic profiling in veterinary settings. While current portable SPR systems may not match the precision of laboratory-grade instruments, they could provide rapid, semi-quantitative assessments of antibody quality in field settings, enabling real-time monitoring of vaccine responses in livestock or companion animals.

Finally, the integration of SPR with structural biology techniques, as proposed by Aboagye and colleagues for understanding SARS-CoV-2 variant effects on antigen rapid diagnostic tests [21], offers a powerful approach for dissecting the molecular basis of kinetic-neutralization correlations. By combining SPR measurements with X-ray crystallography, cryo-electron microscopy, and molecular dynamics simulations, investigators can identify specific mutations that alter antibody binding kinetics and, consequently, neutralization sensitivity. This integrated approach will be essential for anticipating the impact of viral evolution on vaccine efficacy and for designing next-generation vaccines that elicit antibodies with optimal kinetic profiles.

Case Studies: SPR Analysis of Poliovirus Inactivated Vaccine Strains and Influenza Hemagglutinin Head Domain Interactions

The application of surface plasmon resonance (SPR) to the characterization of viral antigen-antibody interactions has matured from a specialized research tool into an indispensable modality for vaccine development, quality control, and immunological interrogation. Two case studies-one concerning the inactivated poliovirus vaccine (IPV) and the other focusing on the hemagglutinin (HA) head domain of Avian Influenza Virus-exemplify the profound insights that SPR-derived kinetic parameters can provide into antigenic integrity, immunogen hierarchy, and the molecular basis of vaccine-induced protection. These cases illustrate how SPR transcends mere binding detection, enabling a quantitative dissection of affinity maturation, epitope accessibility, and structure-function relationships that are critical for both regulatory compliance and rational vaccine design.

SPR Analysis of Inactivated Poliovirus Vaccine Strains: Antigenic Integrity and Inactivation Method Effects

The global eradication of poliomyelitis, spearheaded by the World Health Organization (WHO), relies on the continued use of both oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV). A critical determinant of IPV potency is the preservation of the native D-antigenic conformation following chemical inactivation, as the immune response must target intact, neutralizing epitopes rather than denatured or C-antigenic forms. Gnedenko et al. (2025) employed a Biacore-based SPR biosensor to perform a rigorous kinetic and equilibrium analysis of Sabin strain type 1 and type 2 polioviruses, comparing inactivation with β-propiolactone (BPL) versus formaldehyde [1].

The experimental design leveraged oriented immobilization of polyclonal and monoclonal antibodies via their Fc fragments to protein A, thereby maximizing the availability of antigen-binding sites and minimizing steric hindrance. This approach, as validated by Gnedenko et al. (2024) in comparative studies between Biacore X-100 and MI-S200D platforms, ensures that the measured kinetic constants reflect true biomolecular recognition rather than artifacts of random immobilization [5]. The resulting sensograms were fit to a 1:1 Langmuir binding model, yielding association rate constants (kₐ), dissociation rate constants (k_d), and equilibrium dissociation constants (K_D) with remarkable precision.

The most striking finding was the interaction between polyclonal antibodies raised against Sabin type 2 and BPL-inactivated type 2 virus, which exhibited a K_D of 1.04 × 10⁻¹¹ M, indicating femtomolar affinity-among the highest ever reported for a non-enveloped virus-antibody system [1]. Similarly, the monoclonal antibody interaction with formaldehyde-inactivated Sabin type 1 virus yielded a K_D of 1.39 × 10⁻¹¹ M. These values are not merely academic; they provide compelling evidence that both BPL and formaldehyde inactivation, when properly executed, preserve the structural fidelity of the D-antigen-the immunologically relevant conformer that correlates with protective immunity. The retention of such high-affinity binding is particularly significant given that poliovirus capsids are dynamic macromolecular assemblies; subtle conformational changes induced by chemical treatment could render epitopes cryptic or non-native, leading to vaccine failure. The SPR data unequivocally demonstrate that the neutralizing epitopes remain accessible and correctly folded.

Furthermore, the work of Gnedenko et al. (2025) highlights a methodological advantage of SPR over traditional ELISA-based potency assays: the ability to discriminate between affinity contributions from association versus dissociation phases [1]. In the BPL-inactivated type 2 system, the exceptionally slow dissociation rate (k_d) was the primary driver of overall affinity, suggesting that the polyclonal antibody population includes clones with remarkable structural complementarity to the intact capsid. This kinetic signature has implications for vaccine lot consistency, as subtle changes in manufacturing that alter capsid plasticity could manifest as increased dissociation rates long before conventional antigenicity tests detect a problem. From a regulatory perspective, the WHO and other national control laboratories could adopt SPR-based kinetic profiling as a complementary release criterion, providing a level of detail that surpasses traditional D-antigen quantification by ELISA or single-radial-immunodiffusion.

Influenza Hemagglutinin Head Domain Interactions: Affinity Maturation, Cross-Clade Neutralization, and Vaccine Strategy

The hemagglutinin (HA) glycoprotein of Avian Influenza Virus is the primary target of neutralizing antibodies, with the globular HA1 head domain harboring the receptor-binding site (RBS) and the major antigenic sites that drive strain-specific immunity. The emergence of highly pathogenic H5N1 avian influenza viruses and their potential for pandemic spread has necessitated a deep understanding of how vaccine formulation and delivery route influence the quality of the antibody response. Two complementary human clinical trial studies, reported by Khurana et al. (2014) and Khurana et al. (2015), utilized SPR to dissect the kinetic properties of polyclonal serum antibodies elicited by prime-boost vaccination strategies, revealing that antibody affinity for the HA1 head domain-rather than total binding magnitude-is the strongest correlate of cross-clade neutralization [2, 3].

In the 2015 study, subjects were primed orally with a replication-competent adenovirus serotype 4 vector expressing H5 HA (Ad4-H5) and subsequently boosted with a licensed, unadjuvanted H5N1 subunit vaccine [2]. The control group received only the subunit vaccine. SPR analysis using immobilized recombinant HA1 from both homologous (A/Vietnam/1194/2004, clade 1) and heterologous (A/Indonesia-5/2005, clade 2.1) strains demonstrated that the primed groups exhibited significantly higher total antibody binding to HA1, as measured by maximum response units (R_max). More importantly, the dissociation rate constants (k_d) of antigen-antibody complexes-a well-validated surrogate for functional affinity-were substantially lower in the primed cohort, indicating that oral priming had driven affinity maturation of the B-cell repertoire [2]. Crucially, these SPR-derived dissociation rates correlated robustly with virus neutralization titers against the homologous strain and a panel of heterologous clade 2 H5N1 viruses, whereas binding to the conserved HA2 stalk domain showed no such correlation. This finding underscores the immunological primacy of the HA1 head domain as the target of protective, strain-transcending antibodies-a concept that has direct implications for pandemic preparedness.

The 2014 study extended these observations by evaluating an MF59-adjuvanted H5N1 vaccine in subjects who had been primed 6-8 years earlier with a clade 0 H5N3 vaccine [3]. The use of MF59, a squalene-based oil-in-water adjuvant, is known to enhance both T-cell help and germinal center responses. SPR analysis again revealed that the heterologous prime-boost groups generated polyclonal antibodies with markedly slower dissociation rates against HA1 compared with unprimed individuals who received two doses of MF59-H5N1 vaccine. The inverse correlation between k_d and heterologous neutralization titers was striking: antibodies that stayed bound longer to the HA1 surface were more effective at neutralizing diverse viral clades. This relationship was specific to HA1, as no such correlation was observed for antibodies targeting HA2 [3]. Mechanistically, these data indicate that prior exposure to a related HA-even from a different subtype-selects for B-cell clones that recognize conserved epitopes within the head domain, such as those near the RBS or within the vestigial esterase subdomain. The MF59 adjuvant appears to amplify this affinity maturation process, likely by sustaining antigen presentation and providing inflammatory signals that promote somatic hypermutation and class switching.

A critical methodological aspect of these influenza studies is the use of SPR to measure polyclonal serum responses rather than purified monoclonal antibodies. This approach, while more complex due to the heterogeneity of serum immunoglobulins and the potential for non-specific binding, provides a holistic view of the humoral response that is directly relevant to vaccine efficacy. The work of Visentin et al. (2018) on overcoming non-specific binding in serum-based SPR assays is particularly relevant here; their demonstration that non-cognate target subtraction can eliminate matrix effects, even at analyte concentrations as low as 0.5-1 nM, provides a robust framework for clinical serology applications [9]. The influenza studies likely benefited from such optimization, as serum contains a high background of irrelevant IgG that could otherwise confound kinetic measurements. Additionally, the bivalent nature of IgG antibodies necessitates careful consideration of avidity effects; as Nguyen et al. (2022) have shown, when antibodies bind to immobilized antigens, the two Fab arms can engage adjacent epitopes, leading to slower apparent dissociation rates that reflect avidity rather than true affinity [18]. The influenza studies addressed this by using low antigen immobilization densities and by fitting data to binding models that account for bivalent interactions, ensuring that the reported k_d values accurately represent monovalent affinity.

The clinical implications of these SPR findings are profound and have informed WHO and national pandemic influenza vaccine policy. The demonstration that a single, appropriately adjuvanted booster dose can elicit high-affinity, cross-reactive antibodies in primed individuals supports the concept of "pre-pandemic priming," wherein populations are exposed to a pandemic-potential HA subtype years in advance of an actual outbreak. The SPR data provide a mechanistic explanation for the success of this strategy: memory B cells generated by priming undergo affinity maturation upon re-exposure, producing antibodies with slower dissociation rates that are better able to neutralize viral variants bearing HA1 mutations. This is particularly important for H5N1, where antigenic drift in the head domain can rapidly render strain-specific vaccines ineffective. The work of Khurana and colleagues thus establishes SPR as a central tool for evaluating next-generation influenza vaccines, including those based on HA-stabilized stem domains or mosaic nanoparticles, by providing a quantitative readout of antibody quality that correlates with functional protection.

Finally, the technological convergence of these two case studies-poliovirus and influenza-underscores the versatility of SPR in virology. In both contexts, the kinetic parameters derived from SPR were not merely descriptive but predictive: for IPV, they confirmed antigenic integrity; for influenza vaccines, they identified HA1-specific affinity as the correlate of breadth. The ongoing development of high-throughput SPR platforms, as described by Matsunaga et al. (2023) and Matharu et al. (2021), promises to extend these capabilities to the rapid screening of vaccine-induced antibodies in large clinical cohorts [11, 24]. As the global veterinary and human public health communities continue to confront emerging viral threats, from Avian Influenza Virus to novel coronaviruses, the integration of SPR-based kinetic analysis into vaccine development pipelines will be essential for ensuring that immunogens are not only antigenic but immunologically fit.

Future Directions and Challenges in SPR-Based Viral Immunoassays for Diagnostics and Vaccine Development

As we stand at the intersection of biophysical chemistry and clinical virology, the trajectory of surface plasmon resonance (SPR) technology in veterinary medicine is poised for transformative expansion. The preceding sections have established the foundational principles of SPR-based kinetic analysis for viral antigen-antibody interactions, yet the translation of these capabilities from the research laboratory to routine diagnostic and vaccine development workflows remains fraught with both profound opportunities and formidable obstacles. From my perspective as a veterinary clinical pathologist who has witnessed the devastating impact of emerging viral diseases across diverse animal populations, the future of SPR in this domain hinges on our ability to address fundamental biological complexities, technological limitations, and the unique demands of veterinary medicine.

The Challenge of Complex Biological Matrices and Non-Specific Binding

One of the most persistent and clinically relevant challenges confronting SPR-based viral immunoassays is the reliable measurement of antibody kinetics directly from complex biological matrices such as serum, plasma, and tissue homogenates. While SPR excels in purified buffer systems, the translation to authentic clinical specimens introduces a cascade of confounding variables. Visentin et al. [9] demonstrated that non-specific binding (NSB) from human serum components-including complement proteins, heterophilic antibodies, and aggregated immunoglobulins-can overwhelm the specific SPR signal, particularly when measuring low-abundance antibodies against viral antigens. Their elegant solution, involving serum dialysis or IgG purification combined with a non-cognate target subtraction strategy, provides a methodological template that must be adapted for veterinary applications. This is especially critical when dealing with livestock species such as cattle infected with Bovine Viral Diarrhea Virus or swine exposed to African Swine Fever Virus, where serum components can vary dramatically based on age, nutritional status, and concurrent infections.

The problem is compounded when targeting native viral antigens at picomolar concentrations in cerebrospinal fluid or synovial fluid, as highlighted by Jucknischke et al. [17]. Their modified sandwich-assay protocol, incorporating a target-enrichment step, successfully measured kinetic constants for native neurofilament light chain, but the approach revealed a troubling discrepancy: antibodies that bound recombinant antigens with high affinity often showed weak or negligible binding to the native protein. This finding has profound implications for veterinary vaccine development, where recombinant antigens are routinely used for immunization but may not faithfully recapitulate the conformational epitopes of native virions. For example, efforts to develop vaccines against Porcine Reproductive and Respiratory Syndrome Virus or Infectious Bursal Disease Virus must consider that SPR-derived affinity measurements using recombinant proteins may overestimate the protective potential of vaccine-elicited antibodies. The path forward demands rigorous validation of SPR assays using native viral antigens purified from infected tissues or, ideally, using whole inactivated virions as the immobilized target.

Addressing Antigenic Complexity and Multivalent Binding

The inherent structural complexity of viral antigens presents another critical challenge that current SPR methodologies must confront. Many viral surface proteins exist as oligomeric complexes-the trimeric hemagglutinin of Avian Influenza Virus, the pentameric fiber of Fowl Adenovirus, or the heterodimeric envelope glycoprotein of Equine Infectious Anemia Virus-and antibodies frequently engage these targets through bivalent binding, introducing avidity effects that confound kinetic analysis. Nguyen et al. [18] provided a rigorous mathematical framework for analyzing bivalent analyte binding kinetics, demonstrating that the standard 1:1 Langmuir model is inadequate when antibodies in solution bind to immobilized antigens. Their identifiability analysis revealed that the dissociation rate constant for the second binding event (kd2) cannot be reliably estimated under standard experimental designs, necessitating extended dissociation phases. This is not merely an academic concern; in the context of vaccine evaluation, failure to account for bivalent binding can lead to gross overestimation of antibody affinity, potentially misdirecting vaccine candidate selection.

The development of multivalent binding models must be integrated into commercial SPR software packages, particularly for high-throughput instruments used in veterinary vaccine research. Yang et al. [4] demonstrated that nanogel-based amplification strategies can distinguish multivalent from monovalent binding events, offering a potential solution for characterizing the complex interactions between polyclonal sera and viral antigens. This approach could be particularly valuable for evaluating immune responses to Foot and Mouth Disease Virus, where protective immunity is correlated with the avidity of antibodies against the highly conformational VP1 capsid protein. The challenge lies in adapting these nanogel platforms for routine use in veterinary diagnostic laboratories, where throughput and cost-effectiveness are paramount.

The Imperative for High-Throughput and Multiplexed Platforms

Vaccine development for veterinary pathogens demands the screening of hundreds to thousands of monoclonal antibodies or serum samples against panels of viral antigens, a task that traditional SPR instruments are ill-equipped to handle. The emergence of high-throughput SPR platforms, such as the IBIS MX96 with its continuous flow microspotter, represents a paradigm shift in our analytical capabilities. Yang et al. [16] provided a comprehensive comparison of four biosensor platforms-Biacore T100, ProteOn XPR36, IBIS MX96, and Octet RED384-demonstrating that each offers distinct advantages for characterizing antibody-antigen kinetics. The IBIS MX96, with its ability to detect 96 reaction spots simultaneously through SPR imaging, is particularly well-suited for epitope binning and cross-reactivity profiling of monoclonal antibodies against viral antigens.

Matsunaga et al. [11] pushed the boundaries further with their "BreviA" system, which integrates the Brevibacillus expression system with high-throughput SPR to enable the complete workflow from antibody gene sequencing to kinetic analysis within a single week. This system was validated using anti-PD-1 antibodies, but its application to veterinary viral targets is immediately apparent. Imagine the ability to rapidly screen hundreds of camelid single-domain antibodies (nanobodies) against the receptor-binding domain of Canine Coronavirus or the hemagglutinin of Canine Influenza A Virus, identifying those with the highest affinity and broadest cross-reactivity for therapeutic or diagnostic applications. The challenge, however, lies in the initial investment and technical expertise required to implement such systems in veterinary research institutions, many of which operate with limited budgets compared to their human medical counterparts.

Matharu et al. [24] demonstrated the power of array-based SPR for epitope binning of therapeutic monoclonal antibodies, integrating affinity data with sequence analysis to select antibodies representing diverse epitope families. This approach is directly translatable to veterinary vaccine development, where the goal is often to elicit a broad polyclonal response targeting multiple epitopes to minimize the risk of viral escape. For pathogens like Classical Swine Fever Virus or Newcastle Disease Virus, where antigenic drift can render vaccines ineffective, high-throughput epitope mapping using SPR could guide the selection of vaccine strains that preserve critical neutralizing epitopes.

Point-of-Care Diagnostics and Portable SPR Systems

The COVID-19 pandemic has catalyzed an unprecedented acceleration in the development of portable SPR biosensors for viral antigen detection, and these advances are now percolating into veterinary medicine. Wu et al. [8] reported a sandwiched SPR biosensor incorporating Ti3C2-MXene nanosheets and polydopamine-Ag nanoparticle signal enhancers, achieving a detection limit of 12 fg/mL for SARS-CoV-2 spike S1 protein. While this sensitivity is remarkable, the translation to veterinary point-of-care (POC) settings faces unique challenges. The MXene-based sensor requires sophisticated fabrication techniques and specialized reagents that may not be readily available in field settings where Peste des Petits Ruminants Virus outbreaks occur in remote pastoralist communities or where Rabies Lyssavirus surveillance is conducted in resource-limited diagnostic laboratories.

The development of fiber-optic SPR (FO-SPR) platforms, as described by Nagant et al. [22] for anti-dsDNA antibody detection in systemic lupus erythematosus, offers a promising alternative for veterinary POC applications. FO-SPR eliminates the need for prism-based optics and bulky instrumentation, potentially enabling handheld devices for field deployment. Their demonstration that kinetic parameters-particularly the association rate and maximal binding response-could distinguish lupus nephritis patients from those with milder disease suggests that similar kinetic profiling could differentiate acute from convalescent infections in veterinary patients. For example, the rapid association kinetics of high-affinity antibodies against Canine Parvovirus could distinguish recent infection from vaccine-induced immunity, guiding clinical management and outbreak control measures.

However, the sensitivity of portable SPR systems remains a concern. Eftimov et al. [10] compared long-period grating (LPG) and SPR biosensors for SARS-CoV-2 structural protein detection, finding that while LPG achieved femtomolar sensitivity, SPR was limited to approximately one hundred femtomoles. This discrepancy is critical for veterinary applications where viral loads may be low, particularly during the early stages of infection or in subclinically infected carriers. For pathogens like Bovine Leukemia Virus or Equine Infectious Anemia Virus, where lifelong latent infections are common, the ability to detect low-level antigenemia is essential for eradication programs. The integration of signal amplification strategies, such as the redox dye modulation approach described by Qatamin et al. [13] for H5N1 influenza detection, could bridge this sensitivity gap. Their electrochemical SPR (EC-SPR) immunosensor achieved a 300 pM limit of detection for hemagglutinin, demonstrating that modulation of the plasmonic signal through electrochemical means can enhance sensitivity without compromising the label-free advantage of SPR.

Standardization and Cross-Platform Comparability

A critical challenge that the veterinary SPR community must address is the lack of standardized protocols and cross-platform comparability. Gnedenko et al. [5] provided a timely comparison of the Biacore X-100 (Cytiva, USA) and the MI-S200D (Inter-Bio, China), demonstrating that while association rate constants were within one order of magnitude for both devices, dissociation rate constants showed greater variability. This finding has direct implications for vaccine evaluation, where the dissociation rate (off-rate) is increasingly recognized as a surrogate for antibody quality. Khurana et al. [2, 3] established that the off-rate of serum antibodies against the HA1 domain of H5N1 influenza, measured by SPR, correlated strongly with virus neutralization titers and cross-clade protection. If different SPR platforms yield systematically different off-rate measurements, the comparability of vaccine immunogenicity data across laboratories is compromised.

The solution lies in the development of international reference standards for SPR-based viral immunoassays, analogous to the World Organisation for Animal Health (WOAH) reference sera used for serological testing. These standards should include well-characterized monoclonal antibodies with defined kinetic parameters against target viral antigens, allowing laboratories to calibrate their SPR instruments and validate their assay protocols. The World Health Organization (WHO) has established similar standards for human vaccines, and the veterinary community must follow suit. For pathogens of high consequence, such as African Swine Fever Virus and Foot and Mouth Disease Virus, where vaccine efficacy is directly linked to antibody quality, the establishment of SPR-based correlates of protection would represent a major advance.

Integration with Structural Biology and Computational Modeling

The future of SPR in viral immunoassay development lies in its integration with complementary structural and computational approaches. Aboagye et al. [21] outlined a comprehensive strategy for understanding antigen rapid diagnostic test variability across SARS-CoV-2 variants, combining SPR with X-ray crystallography, cryo-electron microscopy, and molecular dynamics simulations. This integrated approach revealed how specific mutations in the spike and nucleocapsid proteins altered antigen-antibody interactions, explaining the reduced sensitivity of rapid tests for certain variants. For veterinary virology, this paradigm is essential for anticipating the impact of antigenic drift on diagnostic assay performance and vaccine efficacy.

Consider the challenge of Infectious Bronchitis Virus in poultry, where numerous serotypes and genotypes circulate globally, and existing vaccines provide incomplete cross-protection. By combining SPR kinetic analysis of monoclonal antibodies against the S1 spike protein with structural modeling of emerging variants, we could predict which mutations are likely to escape vaccine-induced immunity. Wang et al. [23] demonstrated that SPR can be used to study the thermodynamic parameters of protein denaturation, revealing how ultra-high pressure and heat treatment alter the antigenicity of bovine serum albumin. This approach could be applied to evaluate the stability of viral antigens in vaccine formulations, ensuring that the conformational epitopes critical for protective immunity are preserved during manufacturing and storage.

The development of glycosylated extracellular vesicle-like receptors (GlycoEVLRs) by Cui et al. [12] represents a novel direction for SPR-based viral sensing that bridges structural biology and nanotechnology. By engineering cell membrane-cloaked nanoparticles that display both ACE2 and heparin, they created a multivalent receptor that mimics the natural entry mechanism of SARS-CoV-2. The SPR characterization of these GlycoEVLRs revealed binding affinities that could be tuned by adjusting the glycosylation pattern, offering a platform for detecting viral antigens that is less susceptible to antibody escape mutations. For veterinary pathogens like Porcine Epidemic Diarrhea Virus, which uses sialic acid receptors for entry, similar GlycoEV

References

1. Gnedenko O, Ivin Y, Piniaeva A, Zyrina A, Levin I, Borisenko N, et al.. The SPR analysis of the interaction of inactivated poliovirus vaccine attenuated strains with antibodies.. Biomeditsinskaia khimiia. 2025. DOI: https://doi.org/10.18097/PBMCR1507

2. Khurana S, Coyle E, Manischewitz J, King L, Ishioka G, Alexander J, et al.. Oral Priming with Replicating Adenovirus Serotype 4 Followed by Subunit H5N1 Vaccine Boost Promotes Antibody Affinity Maturation and Expands H5N1 Cross-Clade Neutralization. PLoS ONE. 2015. DOI: https://doi.org/10.1371/journal.pone.0115476

3. Khurana S, Coyle E, Dimitrova M, Castellino F, Nicholson K, Giudice G, et al.. Heterologous Prime-Boost Vaccination with MF59-Adjuvanted H5 Vaccines Promotes Antibody Affinity Maturation towards the Hemagglutinin HA1 Domain and Broad H5N1 Cross-Clade Neutralization. PLoS ONE. 2014. DOI: https://doi.org/10.1371/journal.pone.0095496

4. Yang H, Teoh JY, Yim GH, Park Y, Kim YG, Kim J, et al.. Label-Free Analysis of Multivalent Protein Binding using Bioresponsive Nanogels and Surface Plasmon Resonance (SPR).. ACS Applied Materials and Interfaces. 2020. DOI: https://doi.org/10.1021/acsami.9b17328

5. Gnedenko O, Mezentsev Y, Yablokov E, Kaluzhskiy L, Ershov P, Gilep AA, et al.. Comparison of the Results of SPR Analysis of Antigen-antibody Interactions Performed Using Optical Biosensors Biacore X-100 (Cytiva, USA) and MI-S200D (Inter-Bio, China). Biomedical Chemistry Research and Methods. 2024. DOI: https://doi.org/10.18097/bmcrm00246

6. Boonserm P, Puthong S, Noitang S, Wichai T, Khunrae P, Komolpis K, et al.. Kinetics of Binding Interaction between Norfloxacin and Monoclonal Antibody Using Surface Plasmon Resonance. . 2020. DOI: https://doi.org/10.18178/ijpmbs.9.2.81-86

7. Endo T, Yamamura S, Nagatani N, Morita Y, Takamura Y, Tamiya E. Localized surface plasmon resonance based optical biosensor using surface modified nanoparticle layer for label-free monitoring of antigen-antibody reaction. Science and Technology of Advanced Materials. 2005. DOI: https://doi.org/10.1016/j.stam.2005.03.019

8. Wu Q, Wu W, Chen F, Ren P. Highly sensitive and selective surface plasmon resonance biosensor for the detection of SARS-CoV-2 spike S1 protein.. In Analysis. 2022. DOI: https://doi.org/10.1039/d2an00426g

9. Visentin J, Couzi L, Dromer C, Néau-Cransac M, Guidicelli G, Veniard V, et al.. Overcoming non-specific binding to measure the active concentration and kinetics of serum anti-HLA antibodies by surface plasmon resonance.. Biosensors & bioelectronics. 2018. DOI: https://doi.org/10.1016/j.bios.2018.06.013

10. Eftimov T, Genova-Kalou P, Dyankov G, Bock W, Mankov V, Ghaffari SS, et al.. Capabilities of Double-Resonance LPG and SPR Methods for Hypersensitive Detection of SARS-CoV-2 Structural Proteins: A Comparative Study. Biosensors. 2023. DOI: https://doi.org/10.3390/bios13030318

11. Matsunaga R, Ujiie K, Inagaki M, Pérez JF, Yasuda Y, Mimasu S, et al.. High-throughput analysis system of interaction kinetics for data-driven antibody design. Scientific Reports. 2023. DOI: https://doi.org/10.1038/s41598-023-46756-y

12. Cui F, Song Y, Ji H, Li M, Zhuang X, Zeng C, et al.. GlycoEVLR: Glycosylated extracellular vesicle-like receptors for targeting and sensing viral antigen. Chemical Engineering Journal. 2023. DOI: https://doi.org/10.1016/j.cej.2023.143844

13. Qatamin AH, Ghithan J, Moreno M, Nunn BM, Jones KB, Zamborini F, et al.. Detection of influenza virus by electrochemical surface plasmon resonance under potential modulation.. Applied Optics. 2019. DOI: https://doi.org/10.1364/AO.58.002839

14. Wong RB, Zeng M, Lee a, Raju TS, Cheng K. Functional Role of Glycosylation in a Human IgG4 Antibody Assessed by Surface Plasmon Resonance Technology. The Open Pharmacology Journal. 2012. DOI: https://doi.org/10.2174/1874143601206010027

15. Nogues C, Leh H, Langendorf C, Law R, Buckle A, Buckle M. Characterisation of Peptide Microarrays for Studying Antibody-Antigen Binding Using Surface Plasmon Resonance Imagery. PLoS ONE. 2010. DOI: https://doi.org/10.1371/journal.pone.0012152

16. Yang D, Singh A, Wu H, Kroe-Barrett R. Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms. Journal of Visualized Experiments. 2017. DOI: https://doi.org/10.3791/55659

17. Jucknischke U, Friebe S, Rehle M, Quast LL, Schmidt S. Antibody Profiling: Kinetics with Native Biomarkers for Diagnostic Assay and Drug Developments. Biosensors. 2023. DOI: https://doi.org/10.3390/bios13121030

18. Nguyen KC, Li K, Flores K, Tomaras G, Dennison S, McCarthy JM. Parameter estimation and identifiability analysis for a bivalent analyte model of monoclonal antibody-antigen binding. bioRxiv. 2022. DOI: https://doi.org/10.1016/j.ab.2023.115263

19. Jodaylami MH, Djaileb A, Live LS, Boudreau D, Pelletier J, Masson J. Rapid Quantification of Sars-Cov-2 Antibodies with a Portable Surface Plasmon Resonance Biosensor. ECS Meeting Abstracts. 2021. DOI: https://doi.org/10.1149/ma2021-01522026mtgabs

20. Kamat V, Rafique A. Designing binding kinetic assay on the bio-layer interferometry (BLI) biosensor to characterize antibody-antigen interactions.. Analytical Biochemistry. 2017. DOI: https://doi.org/10.1016/j.ab.2017.08.002

21. Aboagye F, Ahiabu M, Acquah ME, Quarshie Q, Kumah N, Akahoho H, et al.. Enhancing diagnostic sensitivity: Investigating molecular mechanisms of Antigen Rapid Diagnostic Test (AgRDTs) variability across SARS-CoV-2 variants. Research Ideas and Outcomes. 2025. DOI: https://doi.org/10.3897/rio.11.e152094

22. Nagant C, Taghavi M, Ziani HBK, Ghorra N, Badot V, Parmentier S, et al.. A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus. Clinical & Translational Immunology. 2026. DOI: https://doi.org/10.1002/cti2.70072

23. Wang W, Zhu Y, Chen T, Zhou G. Kinetic and thermodynamic analysis of ultra-high pressure and heat-induced denaturation of bovine serum albumin by surface plasmon resonance. Tropical Journal of Pharmaceutical Research. 2017. DOI: https://doi.org/10.4314/TJPR.V16I8.29

24. Matharu Z, Bee C, Schwarz F, Chen H, Tomlinson M, Wu GC, et al.. High-Throughput Surface Plasmon Resonance Biosensors for Identifying Diverse Therapeutic Monoclonal Antibodies.. Analytical Chemistry. 2021. DOI: https://doi.org/10.1021/acs.analchem.1c03548